SARS News and Research

RSS

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

A new research letter assessed patients hospitalized with a positive SARS-CoV-2 test during the fourth wave compared to the previous waves.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Siemens Healthineers Announces FDA Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test

The CLINITEST Rapid COVID-19 Antigen Self-Test has received FDA EUA for unsupervised self-testing for the SARS-CoV-2 virus by individuals age 14 and older (or adult-collected samples from individuals ages 2-13).

From Siemens Healthineers 4 Jan 2022

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.

From Sino Biological Inc. 4 Jan 2022

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants.

3 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

SARS-CoV-2 differs from other viruses in the beta coronavirus family in the activation of a key pathway associated with endoplasmic reticulum stress.

3 Jan 2022

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Researchers designed molecular probes of diverse SARS-CoV-2 variants and evaluated their antibody binding specificity.

3 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

Researchers use data and a mathematical model to determine the impact of the SARS-CoV-2 Omicron variant on future risk of infection.

3 Jan 2022

CDC report shows COVID vaccines safe for children, serious side effects rare

Researchers determine the characteristics and clinical outcomes of COVID-19 in children and adolescents 18 years or younger.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

Researchers study the nucleotide sequences of the newly emerged SARS-CoV-2 Omicron variant with other nucleotide sequences in the GISAID database.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

COVID-19 tests with the new assay may be just as reliable as laboratory-based molecular tests

Researchers at the University of Illinois Chicago have designed a high-quality assay that can be used in at-home tests for rapid COVID-19 screening.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Researchers investigate the ability of immunity acquired from SARS-CoV-2 wild-type infection to protect against the Omicron variant in Syrian hamster models.

3 Jan 2022

SARS News and Research

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Siemens Healthineers Announces FDA Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

The impact of natural selection on sequence diversity in SARS-CoV-2

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

CDC report shows COVID vaccines safe for children, serious side effects rare

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

COVID-19 tests with the new assay may be just as reliable as laboratory-based molecular tests

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News